AMNOG 2.0: How Germany is debating the future of benefit assessment
AMNOG 2.0 is the emerging debate about how Germany should balance early access to innovative medicines, robust evidence requirements and the financial sustainability of its statutory health insurance system. Some innovative medicines enter the market with greater evidence uncertainty, additional evidence may only become available after launch, while healthcare expenditure continues to rise.
The debate also matters beyond Germany. The EU Health Technology Assessment (HTA) Regulation has introduced Joint Clinical Assessments (JCAs), creating a common European clinical assessment that feeds into national HTA processes. JCAs have applied to new oncology medicines and advanced therapy medicinal products (ATMPs) since January 2025; orphan medicines will follow in 2028 and all new centrally authorised medicines in 2030. Germany is therefore discussing the future of AMNOG while the European evidence environment is changing. AMNOG 2.0 is not an enacted reform package at this stage, but an ongoing policy debate.
Four questions define the AMNOG 2.0 debate
- How early should patients gain access to innovative medicines?
- How much evidence should be required at market entry to establish added benefit?
- How should additional evidence generated after launch feed back into benefit assessment?
- How can early access to innovation remain financially sustainable?
Orphan medicines, ATMPs and targeted therapies can involve small populations, limited comparative evidence or uncertainty about long-term outcomes at launch. Industry proposals therefore call for greater flexibility in specific treatment situations and use of the best available evidence. At the same time, statutory health insurance expenditure remains under pressure. The resulting policy question is how uncertainty should be managed when early access, evidence requirements and financing pull in different directions.
How much evidence should AMNOG require at market entry?
The first major reform question concerns the evidence threshold for medicines addressing significant medical need when their evidence base remains uncertain at launch. According to the GKV-Spitzenverband, the BMG has discussed special treatment for medicines with regulatory designations including PRIME, Accelerated Assessment, Conditional Marketing Authorisation and authorisation under exceptional circumstances. Under the approach described by the GKV-Spitzenverband, a positive quantified added benefit could be recognised despite greater uncertainty in the underlying evidence.
The problem is particularly visible in small populations and severe diseases. Conventional comparative evidence can be difficult to generate before launch, and long-term outcomes may not yet be observable. Reform proposals therefore include formal recognition of specific treatment situations and greater consideration of the best evidence that can reasonably be generated. The counterargument is that marketing authorisation and German early benefit assessment answer different questions: authorisation concerns the benefit-risk balance, while AMNOG asks whether patient-relevant added benefit is demonstrated against the comparator relevant to German care.
What could change?
A lower or more flexible initial evidence threshold would make management of residual uncertainty after launch more important. The evidence pathway could increasingly look like this: marketing authorisation → initial benefit assessment → additional evidence generation → reassessment. The key question would be which remaining uncertainties can realistically be resolved afterwards.
How should post-launch evidence feed into AMNOG reassessment?
According to the GKV-Spitzenverband’s description of the BMG proposals, regular reassessments are being considered for certain medicines. Data from Germany’s Health Research Data Centre (Forschungsdatenzentrum Gesundheit, FDZ) could potentially contribute in the future. Longer follow-up, new clinical data cuts and suitable real-world data could become part of a subsequent assessment cycle.
The central disagreement concerns when reassessment is justified. The GKV-Spitzenverband argues that it should primarily take place when the evidence base has materially changed and a meaningful gain in knowledge can be expected. A more systematic model would require manufacturers to anticipate which evidence could become available two, three or more years after launch and which initial uncertainties it could address. The role of German registries, claims data and FDZ data is covered separately in our analysis of Real-World Evidence in the AMNOG dossier.
Which endpoints and evidence standards should apply to AMNOG?
The third reform question concerns how closely German benefit assessment should connect to evidence generated for regulatory approval. According to the GKV-Spitzenverband, the proposals discussed by the BMG would allow endpoints used in the regulatory process to be treated initially as “provisionally patient-relevant” for certain medicines. An endpoint may support a regulatory decision without necessarily meeting German requirements for demonstrating patient-relevant added benefit.
Industry proposals seek greater recognition of endpoints accepted at European level and key endpoints from pivotal regulatory trials. Other proposals call for more flexibility regarding surrogate endpoints and alternative evidence in specific treatment situations. Greater acceptance of regulatory endpoints could make European and regulatory evidence easier to use within German benefit assessment, while making the subsequent management of uncertainty more important.
How predictable should the German comparator be?
The appropriate comparator therapy (zweckmäßige Vergleichstherapie, zVT) is central to AMNOG because it defines the treatment against which added benefit is assessed. The GKV-Spitzenverband calls for an earlier and more binding determination of the zVT. The vfa similarly calls for greater predictability where clinical trials have been designed in accordance with prior advice from Germany’s Federal Joint Committee (Gemeinsamer Bundesausschuss, G-BA).
Clinical evidence generation starts years before an AMNOG dossier is submitted. If the German comparator changes after a pivotal trial has been designed or completed, the evidence may become less directly applicable. A more predictable comparator would improve long-term evidence planning, especially as European PICO scoping, JCA requirements and German comparator requirements increasingly need to be considered within one development programme.
How should AMNOG connect with EU HTA?
Under the EU HTA Regulation, JCAs provide a scientific analysis of the relative clinical effects of a health technology. They support national HTA processes rather than replacing national decisions on added value, reimbursement or pricing. The first JCA report for a medicine was published in June 2026, turning the European framework into an operational assessment process. Germany’s Pharmaceutical and Medical Technology Dialogue places benefit assessment and EU HTA within the same working group.
The vfa calls for greater use of European assessment results within AMNOG, closer alignment of analytical requirements, greater consideration of European endpoints and better timing between JCA and the national process. For manufacturers, early alignment of PICO, endpoints, comparator strategy and evidence generation will become even more important. The German concept of the delta dossier describes the additional national evidence and analyses required to translate the European JCA evidence package into a dossier that meets German AMNOG requirements; it is not an official regulatory designation.
Why are orphan medicines and ATMPs central to the debate?
Orphan medicines and ATMPs concentrate many of the tensions behind AMNOG 2.0. Small patient populations, limited comparative evidence, potentially long-lasting treatment effects and difficult trial conditions can make conventional evidence generation challenging. ATMPs have been subject to mandatory JCA since January 2025, while orphan medicinal products will enter the scope in January 2028.
German reform proposals include formal recognition of specific treatment situations, greater use of alternative evidence and stronger integration of real-world data. Assessment could become more explicitly dependent on the treatment situation and the evidence that can reasonably be generated within it. This increases the importance of distinguishing feasible conventional comparative evidence from situations requiring alternative designs, later evidence generation or greater uncertainty.
How can early access and financial sustainability be reconciled?
Behind the methodological debate lies a broader trade-off between rapid access to innovation and the financial sustainability of Germany’s statutory health insurance system. The BMG describes rapid availability of new medicines as an existing strength, while its Pharmaceutical and Medical Technology Dialogue aims to strengthen innovation and security of supply while containing increases in healthcare costs. In the first half of 2026, expenditure growth across statutory health insurance remained above the growth of contribution-based revenues.
The fundamental question is how much evidence uncertainty a solidarity-based healthcare system should accept in exchange for earlier access to innovative medicines, and how that uncertainty should later be reflected in evidence generation, reassessment and reimbursement.
What AMNOG 2.0 could mean for evidence planning and market access
- Evidence planning could extend further beyond launch if reassessment becomes more systematic.
- Regulatory and HTA evidence could become more closely connected, increasing the importance of coordination between Regulatory Affairs, Clinical Development, HEOR and Market Access.
- European and German evidence strategies could converge further through the sequence: clinical development and PICO planning → JCA → AMNOG → additional evidence generation → potential reassessment.
AMNOG 2.0 is ultimately a debate about managing uncertainty
The current reform discussion does not necessarily challenge the fundamental purpose of AMNOG. It challenges when evidence needs to be available and how uncertainty should be handled over time. The answers will determine not only how Germany develops its benefit assessment system, but also how clinical development, EU HTA and national market access connect in the future. The precise requirements will depend on which proposals ultimately move into legislation.